|
|
Deciphering the Disease Modifying Treatments for Alzheimer's Disease
|
|
Facebook
LinkedIn
E-Mail
|
(2561)
|
Released: 05/16/2024
Expires: 06/30/2025 (subject to change) - CE for this activity will not be available after this date.
Webinar Date and Time: 6/13/2024 from 12:00-1:30 PM CTOnDemand Viewing Now Available!
Overview
The prevalence of Alzheimer's disease in the United States is predicted to double from about 6.7 million in 2023 to 13.8 million by 2050. Historically, diagnosis was made quite late in the disease state, however, with the advent of disease modifying treatments for AD, which confer their benefit in the early stages of disease, comes a paradigm shift in the way that healthcare providers think about this disease. In this program, faculty experts Drs. Clevenger and Romano discuss the importance of early diagnosis, the data supporting the efficacy and safety of disease modifying therapy for AD and the role of the primary care provider.
Objectives- Discuss the importance of early diagnosis of Alzheimer’s disease with regard to disease-modifying treatment benefits.
- Examine the clinical trial data supporting the efficacy and safety of disease-modifying treatments in the treatment of Alzheimer's disease.
- Summarize strategies for improving patient access to disease-modifying therapies for Alzheimer’s disease.
Speakers
Carolyn K Clevenger, DNP, GNP-BC, FAANP, FGSA, FAAN
Raymond Romano, PhD, MPH, RN, FNP-BC
Disclosure
This program was planned in accordance with AANP CE Standards and Policies.
Speaker Disclosures:
- Dr. Carolyn Clevenger is on advisory boards for Lilly and Otsuka on the topic of Alzheimer's disease.
- Raymond Romano has no relevant financial relationships to disclose.
All Planners involved in this activity have no relevant financial relationships to disclose. This program is supported by an independent educational grant from Eisai.
Disclaimer
Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
CE Credit Instructions- Read this activity description, including objectives and disclosures.
- Complete the Pretest associated to the activity.
- Complete the educational content completely:
- Webinar Presentation: Attend the live webinar or watch the recorded on-demand video of the webinar.
- Review all additional materials provided (handouts, post-test reviews, any other downloadable resources).
- After completing all content, click on the blue Next Steps button:
- Complete the post-test.
- Submit the evaluation to receive full AANP CE/Rx credit.
Additional Information
For questions or more information concerning this online CE activity, please visit the AANP Help Center to find answers to frequently asked questions and request assistance.
1.6 Contact Hour(s) of CE,
0.5 of which may be applied towards Pharmacology
|
|
|
|
Adding Registration, Please wait...
